-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 8th, the "2019 Pudong New Area Economic Outstanding Contribution Enterprise Recognition Event" hosted by the People's Government of Pudong New Area of Shanghai was held in Shanghai, and Ding Pharmaceuticals was awarded the "Top 20 Outstanding Contributions of High-Growth Enterprises in Pudong New Area in 2019".
Yu Shuizhong, Chief Operating Officer of Reding Pharmaceutical Research and Development, attended the recognition event and received an honorary certificate from the leadership of the new district.
Biopharmaceuticals is one of the six major 100 billion-scale hard-core industries in Pudong New Area, as an outstanding representative of Pudong Biopharmaceutical Industry, and then Ding Pharmaceuticals makes full use of its unique industry-first position, seizes great opportunities in the rapidly rising Chinese market, and strives to build the world's leading biopharmaceutical companies, which has played a positive role in the construction of the Pudong New Area free trade zone and science and technology center.
6 years since its establishment, Weding has benefited from Pudong's high-quality entrepreneurial and innovative environment, relying on Pudong's policies, talents, resources and other advantages, rapid growth and growth.
At present, Reding Pharmaceuticals continues to expand the industrial scale and global layout, there are currently 2 products in the commercial stage, 16 products and drug candidates, 30 ongoing and planned clinical research, nearly a thousand employees, set up a strong drug research and development and transformation research capabilities of the internal team, and gradually build a drug candidate pipeline with international intellectual property rights, step by step to grow into a fully integrated biopharmaceutical company.
About Reding Pharmaceuticals (NASDAQ: ZLAB; Hong Kong Stock Exchange: 9688) is an innovative biopharmaceutical company in the commercial phase dedicated to providing innovative drugs to patients with cancer, autoimmune and infectious diseases in China and around the world.
we are committed to meeting the enormous unseeded medical needs of the fast-growing pharmaceutical market.
to achieve this goal, the company's experienced team has established strategic partnerships with the world's leading biopharmaceutical companies to create a broad product pipeline of innovative drugs.
Reding Pharmaceuticals has established an in-house team with strong drug research and development and transformational research capabilities, and will build a pipeline of drug candidates with international intellectual property rights.
our vision is to become a fully integrated and innovative biopharmaceutical company that develops, produces and sells innovative products to promote human health and well-being around the world.
。